In light of the new FDA final guidance on quality agreements, drugmakers and contractors “would be well advised to compare their existing agreements to recommendations in the new guidance to determine whether their agreements are consistent with these recommendations,” Cathy L. Burgess, a food and drug law attorney with Alston & Bird LLP in Washington, told me Nov. 28.
If existing quality agreements take a different approach than what is described in the final guidance, drugmakers and contractors “should ensure that the agreements clearly define the respective roles and responsibilities of the two parties” for compliance with current good manufacturing practice (cGMP) requirements, Burgess said.
The final version of the guidance describes how companies involved in contract drug manufacturing can use quality agreements to ensure compliance with cGMP requirements. Violations of cGMP requirements can result in manufacturers being ordered to take corrective actions or not being approved to sell products. Drugs that aren’t manufactured in compliance with cGMP are considered adulterated.
Burgess said “companies that have relied on checklist templates, or have quality agreement provisions built into commercial agreements are now on notice that FDA does not believe such agreements are adequate or effective in defining roles and responsibilities for manufacturing activities.”
An FDA notice announcing the final guidance was published in the Nov. 23 Federal Register (81 Fed. Reg. 84,597). The draft version of the guidance was issued in May 2013.
My full article on the guidance is at http://www.bna.com/fda-issues-guidance-n73014447801/.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)